1. Home
  2. RYTM vs WSBC Comparison

RYTM vs WSBC Comparison

Compare RYTM & WSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • WSBC
  • Stock Information
  • Founded
  • RYTM 2008
  • WSBC 1870
  • Country
  • RYTM United States
  • WSBC United States
  • Employees
  • RYTM N/A
  • WSBC N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • WSBC Major Banks
  • Sector
  • RYTM Health Care
  • WSBC Finance
  • Exchange
  • RYTM Nasdaq
  • WSBC Nasdaq
  • Market Cap
  • RYTM 3.2B
  • WSBC 2.6B
  • IPO Year
  • RYTM 2017
  • WSBC N/A
  • Fundamental
  • Price
  • RYTM $58.16
  • WSBC $28.26
  • Analyst Decision
  • RYTM Strong Buy
  • WSBC Buy
  • Analyst Count
  • RYTM 12
  • WSBC 5
  • Target Price
  • RYTM $73.58
  • WSBC $40.20
  • AVG Volume (30 Days)
  • RYTM 795.0K
  • WSBC 695.5K
  • Earning Date
  • RYTM 05-06-2025
  • WSBC 04-29-2025
  • Dividend Yield
  • RYTM N/A
  • WSBC 5.10%
  • EPS Growth
  • RYTM N/A
  • WSBC N/A
  • EPS
  • RYTM N/A
  • WSBC 2.26
  • Revenue
  • RYTM $130,126,000.00
  • WSBC $586,985,000.00
  • Revenue This Year
  • RYTM $45.46
  • WSBC $41.90
  • Revenue Next Year
  • RYTM $63.04
  • WSBC $11.86
  • P/E Ratio
  • RYTM N/A
  • WSBC $12.85
  • Revenue Growth
  • RYTM 68.06
  • WSBC 0.50
  • 52 Week Low
  • RYTM $35.17
  • WSBC $25.56
  • 52 Week High
  • RYTM $68.58
  • WSBC $37.36
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.62
  • WSBC 35.63
  • Support Level
  • RYTM $45.91
  • WSBC $26.64
  • Resistance Level
  • RYTM $63.11
  • WSBC $28.99
  • Average True Range (ATR)
  • RYTM 3.46
  • WSBC 1.30
  • MACD
  • RYTM 0.29
  • WSBC -0.27
  • Stochastic Oscillator
  • RYTM 36.33
  • WSBC 33.79

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About WSBC WesBanco Inc.

Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.

Share on Social Networks: